ETF research
XBI: State Street SPDR S&P Biotech ETF research
As of 09-28-2026
XBI has delivered an impressive 64.08% 12m return, but the recent trend has turned with a -6.91% 1m return and negative 3m RS of -4.49%, suggesting momentum is fading. Volatility of 28.2% is the highest of the group, and healthcare sits at neutral rather than overweight in current sector tilts. The fund remains above its 200-day average, so the primary uptrend is intact, but the deteriorating short-term numbers argue for waiting for confirmation rather than chasing strength.
The full thesis, the catalysts to watch and the key risks open with a plan. Compare plans
Research on a fund, not a trade call. We do not publish signals on funds.
More ETF research
Already subscribed? Unlock this device →
Not financial advice. This is the published output of an AI-driven, human-in-the-loop research process on a paper (simulated) account: informational only, not personalized investment advice, and not a solicitation to buy or sell any security. Past performance does not guarantee future results. Do your own research and trade at your own discretion in your own account. See the full disclaimer, terms & privacy.